155 related articles for article (PubMed ID: 7549614)
1. Treating obsessive-compulsive disorder.
Long K; Long R
Nurse Pract Forum; 1995 Sep; 6(3):136-7. PubMed ID: 7549614
[No Abstract] [Full Text] [Related]
2. Psychopharmacology of obsessive-compulsive disorder in Tourette syndrome.
King RA; Riddle MA; Goodman WK
Adv Neurol; 1992; 58():283-91. PubMed ID: 1414634
[No Abstract] [Full Text] [Related]
3. Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram.
Habermeyer B; Fuhr P
Pharmacopsychiatry; 2007 Mar; 40(2):87. PubMed ID: 17447184
[No Abstract] [Full Text] [Related]
4. Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report.
Habermeyer B; Fuhr P; Hiss B; Alber C; Müller-Spahn F
Pharmacopsychiatry; 2006 Sep; 39(5):193-4. PubMed ID: 16944412
[TBL] [Abstract][Full Text] [Related]
5. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
[TBL] [Abstract][Full Text] [Related]
6. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Dwivedi S; Pavuluri M; Heidenreich J; Wright T
J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
[No Abstract] [Full Text] [Related]
7. Selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Drug Ther Bull; 1995 Jun; 33(6):47-8. PubMed ID: 7587998
[No Abstract] [Full Text] [Related]
8. Commentary: considerations on the pharmacological treatment of compulsions and stereotypies with serotonin reuptake inhibitors in pervasive developmental disorders.
Gordon CT
J Autism Dev Disord; 2000 Oct; 30(5):437-8. PubMed ID: 11098880
[No Abstract] [Full Text] [Related]
9. The potential of vortioxetine in treating obsessive-compulsive disorder.
Biswas T
Asian J Psychiatr; 2023 Apr; 82():103460. PubMed ID: 36681041
[No Abstract] [Full Text] [Related]
10. Obsessive-compulsive disorder following cavernous sinus thrombosis.
Garyfallos G; Papazisis G; Katsigiannopoulos K; Bozikas VP; Adamopoulou A
J Neuropsychiatry Clin Neurosci; 2009; 21(4):473-4. PubMed ID: 19996263
[No Abstract] [Full Text] [Related]
11. Pharmacologic management of obsessive-compulsive disorder.
Jackson CW; Morton WA; Lydiard RB
South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine for OCD after brain injury.
Stengler-Wenzke K; Müller U
Am J Psychiatry; 2002 May; 159(5):872. PubMed ID: 11986149
[No Abstract] [Full Text] [Related]
13. Current and potential pharmacological treatments for obsessive-compulsive disorder.
Davidson J; Bjorgvinsson T
Expert Opin Investig Drugs; 2003 Jun; 12(6):993-1001. PubMed ID: 12783603
[TBL] [Abstract][Full Text] [Related]
14. [Physiopathology of obsessive-compulsive disorder--special reference to aspects of the neurochemistry].
Seishin Shinkeigaku Zasshi; 2009; 111(7):796-801. PubMed ID: 19999279
[No Abstract] [Full Text] [Related]
15. Does melatonin mediate the therapeutic effects of 5-HT reuptake inhibitors in obsessive compulsive disorder?
Sandyk R
Int J Neurosci; 1992; 64(1-4):221-3. PubMed ID: 1342043
[No Abstract] [Full Text] [Related]
16. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
Vythilingum B; Cartwright C; Hollander E
Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
Giger JN; Davidhizar R; Poole VL
J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
[No Abstract] [Full Text] [Related]
18. [Obsessive-compulsive disorder and schizophrenia].
Denda K
Ryoikibetsu Shokogun Shirizu; 2003; (38):459-63. PubMed ID: 12877026
[No Abstract] [Full Text] [Related]
19. Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline.
Patzold T; Brüne M
Neuropsychiatry Neuropsychol Behav Neurol; 2002 Sep; 15(3):216-9. PubMed ID: 12218715
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
Weiss EL; Potenza MN; McDougle CJ; Epperson CN
J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
